PURPOSE: In clinical routine somatostatin analogue positron emission tomography/computed tomography (PET/CT) such as (68)Ga-DOTA-Tyr-octreotide (DOTATOC)-PET/CT could substitute conventional (111)In-Octreotide scintigraphy. Immunohistochemistry (IHC) for somatostatin receptor 2 (SSTR2) might be a tool to predict positivity of (68)Ga-DOTATOC in patients where initial staging was not performed, e.g., in incidental findings. We therefore compared a score of SSTR2-IHC with the in vivo standard uptake value (SUV) of preoperative or prebiopsy (68)Ga-DOTATOC PET/CT. MATERIALS AND METHODS: In 18 patients, (68)Ga-DOTATOC PET/CT scans were quantified with SUV calculations and correlated to a cell membrane-based SSTR2-IHC score (ranging from 0 to 3). RESULTS: Negative IHC scores were consistent with SUV values below 10. Furthermore, all score 2 and 3 specimens corresponded with high SUV values (above 15). CONCLUSION: SSTR2-IHC scores correlated well with SUV values and we propose to use SSTR2 immunohistochemistry in patients missing a preoperative PET scan to indicate (68)Ga-DOTATOC-PET/CT as method for restaging and follow-up in individual patients.
«
PURPOSE: In clinical routine somatostatin analogue positron emission tomography/computed tomography (PET/CT) such as (68)Ga-DOTA-Tyr-octreotide (DOTATOC)-PET/CT could substitute conventional (111)In-Octreotide scintigraphy. Immunohistochemistry (IHC) for somatostatin receptor 2 (SSTR2) might be a tool to predict positivity of (68)Ga-DOTATOC in patients where initial staging was not performed, e.g., in incidental findings. We therefore compared a score of SSTR2-IHC with the in vivo standard uptak...
»